Dosing strategies for anticancer drugs: the good, the bad and body-surface area
- 1 September 2002
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (13) , 1677-1684
- https://doi.org/10.1016/s0959-8049(02)00151-x
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing RecommendationsJournal of Clinical Oncology, 2002
- Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin ExposureJournal of Clinical Oncology, 2001
- Poor correlation between body surface area and glomerular filtration rateCancer Chemotherapy and Pharmacology, 2000
- Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator EniluracilJournal of Clinical Oncology, 2000
- The Impact of Obesity and Disease on Busulfan Oral Clearance in AdultsBlood, 1999
- Lean Body Mass as a Predictor of Drug DosageClinical Pharmacokinetics, 1994
- Is Dose Normalization to Weight or Body Surface Area Useful in Adults?JNCI Journal of the National Cancer Institute, 1990
- Human surface area: Comparison of the du bois formula with direct photometric measurementPflügers Archiv - European Journal of Physiology, 1971
- Body size and metabolismHilgardia, 1932
- CLINICAL CALORIMETRYArchives of internal medicine (1908), 1916